Don't let a slump in bio­phar­ma deals get you down — yet; The con­tro­ver­sy on drug prices is tak­ing a toll

End­points as­sess­es the big bio­phar­ma sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Hey, what about that big up­swing pre­dict­ed for bio­phar­ma M&A?

Deal­mak­ers in bio­phar­ma are end­ing April with a con­sid­er­able amount of grum­bling. This was the year that M&A was sup­posed to take off, with a new pres­i­dent bull­ish­ly as­sert­ing plans to re­form tax­es in a way that would free up bil­lions in Big Phar­ma cash held over­seas.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.